Physicians Financial Services Inc. Acquires 570 Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• Physicians Financial Services Inc. increased its stake in Eli Lilly and Company by 18.8%, owning 3,607 shares after acquiring an additional 570 shares in the first quarter.
• Institutional investors now hold 82.53% of Eli Lilly's stocks, with notable increases from GAMMA Investing LLC and Capital International Investors among others.
• Eli Lilly reported earnings of $3.34 per share for the last quarter, missing estimates of $4.64, while revenue increased by 45.2% year-over-year to $12.73 billion.

Physicians Financial Services Inc. increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 18.8% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 3,607 shares of the company's stock after acquiring an additional 570 shares during the quarter. Eli Lilly and Company comprises 1.0% of Physicians Financial Services Inc.'s investment portfolio, making the stock its 27th largest holding. Physicians Financial Services Inc.'s holdings in Eli Lilly and Company were worth $2,979,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in LLY. Garner Asset Management Corp grew its holdings in Eli Lilly and Company by 2.3% during the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock valued at $411,000 after buying an additional 12 shares in the last quarter. Brighton Jones LLC grew its holdings in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after buying an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after buying an additional 40 shares in the last quarter. Orion Capital Management LLC grew its holdings in Eli Lilly and Company by 2.5% during the 4th quarter. Orion Capital Management LLC now owns 1,610 shares of the company's stock valued at $1,243,000 after buying an additional 40 shares in the last quarter. Finally, Bank Pictet & Cie Europe AG grew its holdings in Eli Lilly and Company by 4.1% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company's stock valued at $49,993,000 after buying an additional 2,568 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on LLY. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price objective for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Finally, Cantor Fitzgerald began coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $3.19 during trading on Wednesday, hitting $759.76. 4,330,239 shares of the company's stock traded hands, compared to its average volume of 3,787,390. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock has a market capitalization of $720.05 billion, a P/E ratio of 61.82, a PEG ratio of 1.15 and a beta of 0.40. The business has a 50-day simple moving average of $773.36 and a 200-day simple moving average of $800.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. During the same period last year, the business earned $2.58 earnings per share. The company's quarterly revenue was up 45.2% on a year-over-year basis. As a group, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.79%. Eli Lilly and Company's payout ratio is currently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.